Background: In vitro data and early clinical results suggest that metformin has desirable antineoplastic effects and has a theoretical benefit on castration-resistant prostate cancer (CRPC). Objective: To determine whether the use of metformin would be associated with improved clinical outcomes and a reduction in the development of CRPC. Design, setting, and participants: Data from 2901 consecutive patients (157 metformin, 162 diabetic non-metformin, and 2582 nondiabetic) with localized prostate cancer treated with external-beam radiation therapy from 1992 to 2008 were collected from a single institution in the United States. Intervention: Use of metformin in localized prostate cancer. Outcome measurements and statistical analysis: Univariate and multivariate regression models utilizing k-sample, Fine and Gray, Cox regression, log-rank, and Kaplan-Meier methods to assess prostate-specific antigen-recurrence-free survival (PSA-RFS), distant metastases-free survival (DMFS), prostate cancer-specific mortality (PCSM), overall survival (OS), and development of CRPC. Results and limitations: With a median follow-up of 8.7 yr, the 10-yr actuarial rates for metformin, diabetic non-metformin, and nondiabetic patients for PCSM were 2.7%, 21.9%, and 8.2% (log-rank p 0.001), respectively. Metformin use independently predicted (correcting for PSA, T stage, Gleason score, age, diabetic status, and androgen-deprivation therapy use) improvement in all outcomes compared with the diabetic non-metformin group; PSA-RFS (hazard ratio [HR]: 1.99 [1.24-3.18]; p = 0.004), DMFS (adjusted HR: 3.68 [1.78-7.62]; p < 0.001), and PCSM (HR: 5.15 [1.53-17.35]; p = 0.008). Metformin use was also independently associated with a decrease in the development of CRPC in patients experiencing biochemical failure compared with diabetic non-metformin patients (odds ratio: 14.81 [1.83-119.89]; p = 0.01). The retrospective study design was the primary limitation of the study. Conclusions: To our knowledge, our results are the first clinical data to indicate that metformin use may improve PSA-RFS, DMFS, PCSM, OS, and reduce the development of CRPC in prostate cancer patients. Further validation of metformin's potential benefits is warranted.
1.

Introduction
Prostate cancer is the most common noncutaneous malignancy and second leading cause of cancer death among men in the United States [1] . Although the etiology underlying the development of prostate cancer is complex, a recent consensus statement from the American Cancer Society and the American Diabetes Association emphasized a link between diabetes mellitus and prostate cancer [2] . It is known that cancer patients with diabetes are at increased risk of long-term all-cause mortality compared with their nondiabetic counterparts [3] , and diabetes has been associated with more aggressive disease among prostate cancer patients [4] [5] [6] . A postulated underlying mechanism is the elevated level of several anabolic growth factors including high serum insulin levels, androgens, and insulinlike growth factor (IGF)-1 [7] [8] [9] .
Hyperinsulinemia has deleterious non-cancer-related morbidity but has also been shown to predict for increased prostate cancer mortality [8] . The state of hyperinsulinemia and insulin resistance leads to a decrease in sex hormone-binding globulins, causing an increase in available free unbound androgens that is important in hormone-responsive cancers such as breast and prostate cancer [10] . Complicating the treatment of prostate cancer, treatment with androgen-deprivation therapy (ADT) leads to insulin resistance, which may be involved in the development of castrate-resistant prostate cancer (CRPC) [9] .
These findings have led to increasing interest in pharmacologically targeting pathways of metabolism, especially those involved in the development of insulin resistance. Metformin, a biguanide oral antihyperglycemic agent, abrogates hyperinsulinemia in individuals with and without diabetes [11, 12] , and it may be a promising agent for therapeutic gain in prostate cancer [13] . Supporting this, metformin has been shown to inhibit the proliferation of prostate cancer cell lines in vitro [14, 15] . Molecular mechanisms postulated to underlie the antineoplastic effects of metformin include activation of the adenosine monophosphate-activated protein kinase (AMPK) pathway, thereby inhibiting the mammalian target of rapamycin (mTOR) signaling cascade downstream [14] [15] [16] [17] [18] . Insufficient AMPK activity permits cell growth, making it an attractive target for anticancer therapy.
A few selected reports have shown that metformin has an impact on overall survival among men with prostate cancer; however, none have included prostate cancerspecific outcomes to demonstrate an oncologic benefit of metformin [19, 20] . We hypothesized that the use of metformin in patients with prostate cancer would be associated with improved clinical outcomes. A large cohort of 2901 consecutive men undergoing external-beam radiation therapy (EBRT) for localized prostate cancer was identified, and outcomes of tumor control were compared between patients receiving and not receiving metformin, as well as stratifying by diabetic status in the non-metformin group. Additionally, based on the knowledge that hyperinsulinemia may contribute to the development of CRPC, we investigated the effects of metformin on the development of castration-resistant disease.
Methods
Study design
Institutional review board approval was obtained to conduct this study.
We retrospectively identified 3045 consecutive patients with localized prostate cancer treated with definitive EBRT from January 1992 to December 2008 at Memorial Sloan-Kettering Cancer Center. All patients had biopsy-proven adenocarcinoma with pathology reviewed by a urologic pathologist at our institution. Patients with evidence of lymph node metastasis or distant metastasis by pretreatment computed tomography, magnetic resonance imaging, and/or bone scan, or prior treatment with pelvic radiation or radical prostatectomy were excluded [21] . The remaining 2901 patients formed the study cohort for analysis.
ADT was prescribed at the discretion of the treating physician. Patient data were censored for analysis on January 1, 2012. Salvage therapy after biochemical failure generally consisted of combination ADT and rarely salvage radical prostatectomy.
Study outcomes
In general, patients were followed every 3 mo from the time of completion of treatment for the first year, followed by every 6 mo for the To correct for imbalances between groups, logistical regression modeling was performed. Because all metformin patients were diabetic, and no nondiabetic patients used metformin, tests of interaction were not able to be performed. Table 1 shows the baseline characteristics of the study cohort. The median follow-up for the entire cohort was 8.7 yr. ; p = 0.004).
Results
Study population
Metformin and distant metastases
A total of 5.7% (n = 9) of metformin, 24.1% (n = 39) diabetic non-metformin, and 11.5% (n = 298) of nondiabetic patients developed a distant metastasis. The 10-yr actuarial DMFS was 89.7%, 66.1%, and 86.1%, respectively (log-rank p < 0.001; Fig. 2 A total of 1.9% (n = 3) of metformin, 13.0% (n = 21) diabetic non-metformin, and 6.8% (n = 175) of nondiabetic patients died from prostate cancer. The 10-yr PCSM using competing risk analysis was 2.7%, 21.9%, and 8.2%, respectively (logrank p < 0.001; Fig. 3 ). Using Fine and Gray regression with the metformin group as the reference group demonstrated that PCSM trended for significant detriment in the nondiabetic group (adjusted HR: 2.68 [0.85-8.44]; p = 0.09) and was associated with a significant detriment compared with the diabetic non-metformin group (adjusted HR: 5.15 [1.53-17.35 ]; p = 0.008) ( Table 2) . A subgroup analysis was performed by the NCCN risk group. The 10-yr actuarial cumulative incidence rates of PCSM for low-, intermediate-, and high-risk groups for metformin/diabetic non-metformin/nondiabetic patients were 0.0%, 0.0%, and 1.0% (log-rank p = 0.77), 7.4%, 9.4%, and 4.9% ( p = 0.62), and 10.0%, 32.6%, and 17.1% ( p = 0.001), respectively.
OS was analyzed to ensure metformin was not leading to an unexpected increase in non-cancer-related deaths. The 10-yr actuarial OS rates were 81.6%, 55.4%, and 71.8% for the Fig. 1 -Unadjusted Kaplan-Meier curves for prostate-specific antigen (PSA) relapse-free survival among metformin, diabetic non-metformin, and nondiabetic groups. The univariate unadjusted p value for comparing groups was statistically significant: metformin versus diabetic non-metformin, p < 0.001; metformin versus nondiabetic, p = 0.04; and diabetic non-metformin versus nondiabetic, p = 0.002.
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[ ( F i g . _ 2 ) T D $ F I G ] Fig. 2 -Unadjusted Kaplan-Meier curves for distant metastasis-free survival among metformin, diabetic non-metformin, and nondiabetic groups. The univariate unadjusted p value for comparing groups was statistically significant: metformin versus diabetic non-metformin, p < 0.001; metformin versus nondiabetic, p = 0.11; and diabetic nonmetformin versus nondiabetic, p < 0.001. metformin, diabetic non-metformin, and nondiabetic groups, respectively (log-rank p < 0.001). Cox regression analysis with the metformin group as the reference group demonstrated that OS was nonsignificantly worsened in the nondiabetic group (adjusted HR: 1.38 [0.9-2.11]; p = 0.14) and significantly worsened in the diabetic non-metformin group (adjusted HR: 2.25 [1.38-3.661]; p = 0.001).
Metformin and castration resistance
Of the 26 metformin, 53 diabetic non-metformin, and 666 nondiabetic patients who developed a biochemical failure, 25, 53, and 559 were evaluable for the development of CRPC. A total of 1 (4%), 23 (43%), and 148 (26%) patients went on to develop CRPC (comparisons between all groups p < 0.001) ( Supplementary Fig. 1 ). Using logistical regression to determine associations with CRPC and correct for imbalances ( 
Duration of metformin and outcomes
An exploratory analysis was performed to determine the effect of metformin duration on outcomes. Based on a Cox proportional hazard univariate analysis using metformin use as a continuous variable, duration of metformin use was not associated with PSA-RFS ( p = 0.30), DMFS ( p = 0.86), and PCSM ( p = 0.31).
3.7.
Other diabetic medications and prostate cancer-specific mortality Among diabetic patients, patients who used metformin had a greater use of thiazolidinediones (29% vs 11%; p < 0.001) and a trend for greater use of sulfonureas (59% vs 47%;
[ ( F i g . _ 3 ) T D $ F I G ] Fig. 3 -Unadjusted cumulative incidence function curves for prostate cancer-specific mortality among metformin, diabetic non-metformin, and nondiabetic groups. The univariate unadjusted p value for comparing groups was statistically significant: metformin versus diabetic non-metformin, p = 0.001; metformin versus nondiabetic, p = 0.09; and diabetic non-metformin versus nondiabetic, p < 0.001. p = 0.06) and dipeptidyl peptidase-4 inhibitors (57% vs 19%; p = 0.08) ( Supplementary Table 3 ). To ensure these medications did not confound metformin's impact, a Cox regression analysis was performed. None of the other diabetic medications (sulfonureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, meglitinides, a-glucosidase inhibitors, glucagon-like peptide agonists, and insulin) showed a significant impact on PSA-RFS, DMFS, PCSM, or OS.
Discussion
Our results indicate that metformin use is associated with a significant clinical benefit in patients with prostate cancer undergoing definitive radiotherapy. In multivariate models correcting for imbalances in clinical variables, metformin decreased the risk of PSA recurrence, distant metastasis, and PCSM compared with diabetic non-metformin patients. To our knowledge, this is the first clinical evidence that metformin may improve cancer-specific survival outcomes in prostate cancer. Furthermore, metformin strongly decreased the clinically defined transformation from androgen-sensitive prostate cancer to CRPC. There has been increasing clinical evidence that metformin may be beneficial in the treatment of cancer patients. Population-based studies suggest a decreased incidence of cancer in diabetic patients taking metformin [11, 23] as well as improved survival with metformin use [12, 20, 24, 25] . One retrospective report from the MD Anderson Cancer Center demonstrated an overall survival benefit for prostate cancer patients treated with metformin compared with diabetic controls [20] . However, the survival benefit may have been due to improvements in non-cancer-related mortality because prostate cancer-specific outcomes were not reported. In our analysis, patients treated with radiation therapy with metformin had lower rates of distant metastasis, PCSM, in addition to overall mortality, providing insight into the oncologic benefits of metformin use.
The mechanism of action whereby metformin may target cancer cells continues to be elucidated. Preclinical investigations demonstrate that metformin is capable of inhibiting the growth of numerous cancer cell lines including prostate cancer [7] [8] [9] 26, 6] . This inhibitory effect may be mediated via metformin's modulation of several oncogenic signaling pathways [10, 27, 28] . For example, metformin activates AMPK, resulting in a rapid reduction in protein synthesis and cell growth. Additionally, AMPK is an important inhibitor of the mTOR signaling cascade, which regulates cell growth, cell cycle progression, and angiogenesis [16] . Of note, metformin appears to induce mTOR inhibition through AMPK-independent mechanisms as well [15, 29] . The activation of AMPK causes a reduction in insulin, IGF-1, and androgens, all potent mediators of tumorigenesis and cell growth. Intriguingly, there are data to suggest metformin may specifically target cancer stem cells, which are hypothesized to be resistant to conventional therapies and be a major reason for recurrence following radiation or chemotherapy [30] .
Major benefits of metformin include that it is inexpensive, administered orally, and has an extremely favorable toxicity profile. Mild gastrointestinal upset is the most common side effect, and serious toxicity, such as lactic acidosis, is exceptionally rare [31] . Metformin is also safe in nondiabetic patients and approved for conditions other than diabetes including polycystic ovary syndrome [32] . Targeting metabolic pathways in prostate cancer with metformin is particularly appealing given that one of the mainstays of therapy, ADT, is associated with an increased risk of diabetes, insulin resistance, and the metabolic syndrome [33] . Furthermore, in vitro data have shown that metformin in combination with ADT is more effective in inhibiting prostate cancer colony formation rates than either therapy alone [34] . Thus metformin may increase cancer cytotoxicity while simultaneously mitigating toxicity from other therapies. We did perform a subgroup analysis based on an NCCN risk group and found the greatest benefit to be in the high-risk group. Because highrisk patients are most likely to be on ADT and most likely to develop CRPC, the reduction in the development of castrateresistant disease with metformin may partially explain why the high-risk group experienced the greatest benefit in PCSM.
Multiple prospective trials investigating the efficacy of metformin in cancer are underway, with at least 40 such studies currently registered at www.clinicaltrials.gov. It will take years for these trials not only to accrue, but mature to report on long-term survival outcomes, hence the importance of our findings. For now, we hope the results from retrospective series including metformin's beneficial impact on pathologic complete response rate in breast cancer, associated improved survival in pancreatic cancer, and the results presented here will help guide both preclinical and future clinical trials.
Several limitations of this study need to be noted. Most significantly, given its retrospective nature and the fact that metformin was not a randomized variable, bias from unmeasured confounding variables is possible. The severity and duration of diabetes were difficult to assess accurately and are not reported. BMI data were only available for 453 patients and therefore not included in the analyses. However, it has been shown that obesity is independently associated with prostate cancer-specific outcomes. Insulin levels were not measured to provide mechanistic insights into our hypothesis. Due to the limited number of metformin patients and events that occurred, the methodology of our analyses did not incorporate exposure or time-dependent use of metformin or diabetes. Despite these weaknesses, this is the first study to our knowledge to report significant improvement in prostate cancer-specific outcomes with the use of metformin.
Conclusions
In our retrospective study, diabetic patients with prostate cancer who use metformin have an improvement in cancerspecific outcomes. Metformin users trended for a small but significant improvement compared with nondiabetic patients in these outcomes, which raises the question of what effect metformin may have on nondiabetic patients, especially in the setting of ADT. It appears that part of the clinical effect of the improvement in PCSM is related to the reduction in the development of CRPC. These results add to a growing body of literature suggesting the antineoplastic activity of metformin and may have a future role in the treatment of prostate cancer. These results need to be validated in a prospective manner. This study in part was accepted for an oral presentation at the annual American Society for Radiation Oncology (ASTRO) conference in Boston, Massachusetts, on October 28, 2012.
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